Clinical trials: Neovascular Age Related Macular Degeneration
Choroidal Neovascularization (CNV), Age-related Macular Degeneration (AMD)
A Study Of Early Markers Of Choroidal Neovascularization
Identify early markers of choroidal neovascularization (CNV) in the fellow eye of a patient with CNV in the other eye due to age-related macular degeneration with the expectation of being able to identify patients in need of…
- Conditions
- Choroidal Neovascularization (CNV), Age-related Macular Degeneration (AMD), Early Markers
- Trial name
- NCT00902785
- Testing
- no drug
- Where
- 3 sites in Italy, Portugal and 1 more
- Volunteers
- 100 people
- Sponsor
- Pfizer
Neovascular Macular Degeneration
Aflibercept in Polypoidal Choroidal Vasculopathy
To collect data reflecting the efficacy and safety of aflibercept with and without photodynamic therapy in subjects diagnosed with the polypoidal choroidal vasculopathy subtype of wet age-related macular degeneration
- Trial name
- PLANET (NCT02120950)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321), Visudyne
- Where
- 62 sites in Australia, Germany and 6 more
- Volunteers
- 333 people
- Sponsor
- Bayer
Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.
- Conditions
- Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
- Trial name
- NCT03834753
- Testing
- bevacizumab, ranibizumab
- Where
- 50 sites in United States
- Volunteers
- 228 people
- Sponsor
- Outlook Therapeutics, Inc.
Age-Related Macular Degeneration (AMD)
A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD
The purpose of this study is to explore the safety and efficacy of Macugen given as maintenance therapy in patients who have had initial success with another AMD treatment.
- Trial name
- NCT00354445
- Testing
- pegaptanib sodium (Macugen)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Eyetech Pharmaceuticals
Neovascular Age-related Macular Degeneration
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Neovascular age-related macular degeneration (nAMD), also known as "wet" AMD, is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina.
- Trial name
- NCT07007065
- Testing
- Surabgene Lomparvovec (ABBV-RGX-314), Ranibizumab Control
- Where
- 138 sites in United States, Austria and 15 more
- Volunteers
- 561 people
- Sponsor
- AbbVie
Choroidal Neovascularization, Age-Related Macular Degeneration
Neovascular Age Related Macular Degeneration (AMD), Periocular Corticosteroids, and Photodynamic Therapy (PDT)
Randomized controlled clinical trial of periocular corticosteroids as adjunctive therapy to photodynamic therapy (PDT) for patients with neovascular age-related macular degeneration (AMD).
- Trial name
- NCT00305630
- Testing
- Periocular injection of triamcinolone acetonide 40mg
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Johns Hopkins University
Neovascular Age-Related Macular Degeneration
Russian Registry of Patients With nAMD
A three-year, non-randomized, observational, multicenter prospective nAMD study - patient registry.
- Trial name
- NCT04935411
- Testing
- nAMD
- Where
- Russia
- Volunteers
- 2,665 people
- Sponsor
- Novartis Pharmaceuticals
Macular Degeneration Choroidal Neovascularization
Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration
We aimed to investigate the success rate of a planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab, for nAMD to achieve stability…
- Trial name
- Fixed farcimab (NCT06742307)
- Testing
- Faricimab Injection [Vabysmo]
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Hospital Authority, Hong Kong
Macular Degeneration
Influence of Blue Light Filtering Intraocular Lenses on Daytime Levels of Melatonin
The "blue light hazard" has been reported to cause retinal damage (oxidative stress), particularly to the central fovea due to its energetic, shorter wavelength visible photons, which is why blue-light filtering intraocular…
- Trial name
- BluMel (NCT00444249)
- Testing
- White Alcon IOL, Yellow Alcon IOL, White Hoya IOL
- Where
- Austria
- Volunteers
- 136 people
- Sponsor
- The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Age-Related Macular Degeneration, Geographic Atrophy
Phase 1/2 Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
The Phase 1 safety study of VOY-101 is comprised of escalating dose Cohorts, followed by a Phase 2 at the recommended phase 2 dose.
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy, Non-neovascular AMD, Non-neovascular Age-related Macular Degeneration
- Trial name
- JOURNEY (NCT06087458)
- Testing
- VOY-101
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 60 people
- Sponsor
- Perceive Biotherapeutics, Inc.
Age-Related Macular Degeneration
A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.
The purpose of this study is to compare the ability of different doses of pegaptanib sodium to safely and effectively minimize fluid leakage within the eye, thereby stabilizing or impriving vision in patients with wet AMD when…
- Trial name
- NCT00321997
- Testing
- Pegaptanib sodium
- Volunteers
- 540 people
- Sponsor
- Eyetech Pharmaceuticals
Neovascular Age Related Macular Degeneration
Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients.
This open-label, Phase IV prospective, observational study will evaluate patients, who have been diagnosed with Neovascular Age-Related Macular Degeneration and have previously received either a standard intravitreal injection of…
- Trial name
- NCT01942213
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Prism Vision Group
Neovascular Age-related Macular Degeneration
Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.
The purpose of this study was to identify innovative early imaging parameters as predictors of the long-term clinical response to brolucizumab in terms of fluid resolution in patients with wet Age-related Macular Degeneration…
- Trial name
- IMAGINE (NCT04774926)
- Testing
- Brolucizumab
- Where
- 20 sites in Italy
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Age Related Macular Degeneration, Stargardt's Disease
Stem Cell Therapy for Outer Retinal Degenerations
This study is a Phase I/II , open label,non randomized, prospective study to determine the safety of human embryonic stem cell derived Retinal pigmented epithelium (hESC RPE) sub retinal injections versus hESC RPE seeded on a…
- Conditions
- Age Related Macular Degeneration, Stargardt's Disease, Exudative Age-related Macular Degeneration
- Trial name
- NCT02903576
- Testing
- injection of hESC-RPE in suspension, injection hESC-RPE seeded in a substrate
- Where
- Brazil
- Volunteers
- 15 people
- Sponsor
- Federal University of São Paulo
Age-related Macular Degeneration (AMD)
Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)
This study was a retrospective cohort study of patients to assess the early insights into real-world safety among wet AMD patients initiating brolucizumab.
- Trial name
- NCT05082415
- Testing
- Brolucizumab
- Where
- United States
- Volunteers
- 9,456 people
- Sponsor
- Novartis Pharmaceuticals
Non-exudative Age-related Macular Degeneration, Diabetic Retinopathy
Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy
This pilot study is to determine whether it would be safe and feasible to inject CD34+ stem cells from bone marrow into the eye as treatment for patients who are irreversibly blind from various retinal conditions.
- Conditions
- Non-exudative Age-related Macular Degeneration, Diabetic Retinopathy, Retina Vein Occlusion, Retinitis Pigmentosa
- Trial name
- NCT01736059
- Testing
- CD34+ bone marrow stem cells intravitreal
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, Davis
nAMD
A Study to Compare GNR-139 and Eylea® in Patients With nAMD
This is a multicenter, randomized, double-blind study designed to compare the efficacy and safety of the investigational drug GNR-139 with the reference drug Eylea in treatment-naive patients with neovascular age-related macular…
- Trial name
- NCT07844148
- Testing
- aflibercept, Eylea
- Where
- 14 sites in Russia
- Volunteers
- 180 people
- Sponsor
- AO GENERIUM
Macular Degeneration
Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration
The study will provide additional safety data for specific safety events in persons receiving intravitreal injections. The Committee for Medicinal Products for Human Use (CHMP) is interested in obtaining additional safety…
- Trial name
- NCT00460408
- Testing
- Macugen
- Where
- 68 sites in Belgium, Cyprus and 11 more
- Volunteers
- 501 people
- Sponsor
- Pfizer
Neovascular Age-related Macular Degeneration (nAMD)
A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
Study WR42221 is a Phase IIIb, global, multicenter, randomized, visual assessor-masked study designed to assess the efficacy, safety, and pharmacokinetics of the Port Delivery System with ranibizumab (PDS) 100 mg/mL delivered…
- Trial name
- NCT04657289
- Testing
- Ranibizumab, Port Delivery System with Ranibizumab
- Where
- 104 sites in Argentina, Australia and 14 more
- Volunteers
- 451 people
- Sponsor
- Hoffmann-La Roche
Neovascular Age-related Macular Degeneration
Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration
This is a Phase 1, multicenter, open-label, single- and multi-dose, dose-escalating study of OLX10212 in patients with neovascular age-related macular degeneration (AMD). This study is composed of 2 parts: Part A and Part B.
- Trial name
- NCT05643118
- Testing
- OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Olix Pharmaceuticals, Inc.